Evangelos Briasoulis

Claim Author Page
Publications145
h-index29
Citations2,516
Highly Influential Citations104
  • Publications
  • Influence
Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
  • Evangelos Briasoulis, Haralambos P. Kalofonos, +7 authors Nicolas A. Pavlidis
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2000 (First Publication: 17 September 2000)
    • PURPOSE To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). PATIENTS AND METHODS Seventy-seven consecutive CUP patients (45… Continue Reading
    Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
  • Samuel Murray, Evangelos Briasoulis, Helena Linardou, Dimitrios Bafaloukos, Christos Papadimitriou
  • Medicine
  • Cancer treatment reviews
  • 2012 (First Publication: 1 November 2012)
    • BACKGROUND Taxanes are established in the treatment of metastatic breast cancer (MBC) and early breast cancer (EBC) as potent chemotherapy agents. However, their therapeutic usefulness is limited by… Continue Reading
    Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer
  • Dimitrios H Roukos, Samuel Murray, Evangelos Briasoulis
  • Medicine
  • Cancer biology & therapy
  • 2007 (First Publication: 1 March 2007)
    • The continuous flow of molecular genetic information has cautiously started integrating into clinical practice changing the future landscape of the clinical management of cancer. Germline mutation… Continue Reading
    ‘Classical' but not ‘other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
  • Athanasios G. Pallis, Alexandra Voutsina, +8 authors Vassilios Georgoulias
  • Medicine
  • British Journal of Cancer
  • 2007 (First Publication: 13 November 2007)
    • ‘Classical’ mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine kinase inhibitors (TKIs) in patients with NSCLC. The aim of the… Continue Reading
    A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer
  • Georgios Fountzilas, Urania Dafni, +17 authors Haralambos P. Kalofonos
  • Medicine
  • Breast Cancer Research and Treatment
  • 2008 (First Publication: 1 May 2009)
    • Background Effective anthracycline-free combinations need to be evaluated in metastatic breast cancer (MBC), due to the increased number of patients treated with anthracycline-based adjuvant… Continue Reading